CARBIDOPA, LEVODOPA AND ENTACAPONE

Post-LOE

carbidopa, levodopa and entacapone

Rising

ANDAORALTABLET

Approved

Jan 2022

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

CARBIDOPA, LEVODOPA AND ENTACAPONE (carbidopa, levodopa and entacapone) by Rising is catechol o-methyltransferase inhibitors [moa]. Approved for parkinson's disease. First approved in 2022.

Drug data last refreshed 14h ago

Mechanism of Action

Catechol O-Methyltransferase Inhibitors

Pharmacologic Class:

Aromatic Amino Acid

Indications (1)

Parkinson's disease

Company

Worked on CARBIDOPA, LEVODOPA AND ENTACAPONE at Rising? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.